Sign In to View Organizational & Contract Pricing.
Select a Size
About This Item
Empirical Formula (Hill Notation):
C18H26O3
CAS Number:
Molecular Weight:
290.40
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
MDL number:
Beilstein/REAXYS Number:
5946632
Product Name
Octinoxate, United States Pharmacopeia (USP) Reference Standard
InChI
1S/C18H26O3/c1-4-6-7-15(5-2)14-21-18(19)13-10-16-8-11-17(20-3)12-9-16/h8-13,15H,4-7,14H2,1-3H3/b13-10+
SMILES string
CCCCC(CC)COC(=O)\C=C\c1ccc(OC)cc1
InChI key
YBGZDTIWKVFICR-JLHYYAGUSA-N
grade
pharmaceutical primary standard
API family
octinoxate
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Looking for similar products? Visit Product Comparison Guide
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Application
Octinoxate USP reference standard suitable for use in specified USP compendial quality tests and assays.
Also used to prepare standard and system suitability solution during the assay of Octinoxate by using gas chromatography in conjunction with flame ionization detector.
Also used to prepare standard and system suitability solution during the assay of Octinoxate by using gas chromatography in conjunction with flame ionization detector.
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Other Notes
Sales restrictions may apply.
hcodes
pcodes
Hazard Classifications
Aquatic Chronic 4
Storage Class
10 - Combustible liquids
wgk
WGK 2
flash_point_f
379.4 °F
flash_point_c
193 °C
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Octinoxate
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(3), 3225-3225 (2020)
Timothy P Murphy et al.
Journal of the American College of Cardiology, 65(10), 999-1009 (2015-03-15)
Treatment for claudication that is due to aortoiliac peripheral artery disease (PAD) often relies on stent revascularization (ST). However, supervised exercise (SE) is known to provide comparable short-term (6-month) improvements in functional status and quality of life. Longer-term outcomes are
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service